The U.S. FDA has granted an Emergency Use Authorization for IVOMEC® (ivermectin) 1% Injection, marking the first over-the-counter product authorized to help prevent New World screwworm infestations in cattle amid heightened regional surveillance concerns.
The FDA has conditionally approved Anivive’s Laverdia-CA1 (verdinexor), the first oral SINE-based therapy designed for canine lymphoma, expanding at-home treatment options for both B-cell and T-cell disease.
Elanco has received USDA approval for TruCan™ Ultra B (Oral), the first ½ mL oral Bordetella bronchiseptica vaccine for dogs, designed to deliver proven protection with improved patient comfort.
Elanco Animal Health has received U.S. Department of Agriculture (USDA) approval for Befrena™ (tirnovetmab), an anti-IL31 monoclonal antibody injection providing long-lasting relief for dogs suffering from allergic and atopic dermatitis.
The FDA has granted full approval for Vetmedin (pimobendan) to delay the onset of congestive heart failure in dogs with preclinical myxomatous mitral valve disease—the first animal drug indication to transition from expanded conditional to full approval.
Elanco Animal Health has received full approval from the U.S. Department of Agriculture for Trutect™ (formerly CPMA), the first and only monoclonal antibody therapy proven to treat—and now prevent—deadly canine parvovirus.
Mexico’s SADER approved Merck Animal Health’s EXZOLT® 5% Pour-On (fluralaner 50 mg/mL) for the prevention and treatment of New World Screwworm larvae, strengthening cattle protection and supporting Mexico’s beef industry.
Zoetis has announced the planned retirement of Dr. Rob Polzer, Executive Vice President and President of R&D, at the end of 2025. Dr. Kevin Esch will succeed him as President of Research & Development, effective January 1, 2026.
Dechra has earned Human-Animal Bond Certified Company status, reinforcing its commitment to supporting veterinarians and advancing global awareness of the human-animal bond.
Zoetis’ newly approved Portela® (relfovetmab) becomes the first feline osteoarthritis treatment offering three months of pain relief from a single injection, with EU launch expected in 2026.
Sign up for free to receive the latest veterinary news, product announcements, and industry developments.